SG11201406594UA - Use of high dose laquinimod for treating multiple sclerosis - Google Patents
Use of high dose laquinimod for treating multiple sclerosisInfo
- Publication number
- SG11201406594UA SG11201406594UA SG11201406594UA SG11201406594UA SG11201406594UA SG 11201406594U A SG11201406594U A SG 11201406594UA SG 11201406594U A SG11201406594U A SG 11201406594UA SG 11201406594U A SG11201406594U A SG 11201406594UA SG 11201406594U A SG11201406594U A SG 11201406594UA
- Authority
- SG
- Singapore
- Prior art keywords
- multiple sclerosis
- high dose
- treating multiple
- laquinimod
- dose laquinimod
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 | |
| PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406594UA true SG11201406594UA (en) | 2014-11-27 |
Family
ID=49514859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406594UA SG11201406594UA (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130303569A1 (en) |
| EP (1) | EP2844255A4 (en) |
| JP (2) | JP2015515985A (en) |
| KR (1) | KR20150013658A (en) |
| CN (2) | CN104284663A (en) |
| AR (1) | AR090885A1 (en) |
| AU (1) | AU2013256352A1 (en) |
| BR (1) | BR112014027010A2 (en) |
| CA (1) | CA2870684A1 (en) |
| CL (1) | CL2014002935A1 (en) |
| EA (1) | EA201492010A1 (en) |
| HK (1) | HK1206246A1 (en) |
| IL (1) | IL235337A0 (en) |
| MX (1) | MX2014013039A (en) |
| PE (1) | PE20150161A1 (en) |
| PH (1) | PH12014502447A1 (en) |
| SG (1) | SG11201406594UA (en) |
| TW (2) | TW201347762A (en) |
| UY (1) | UY34775A (en) |
| WO (1) | WO2013166166A1 (en) |
| ZA (1) | ZA201408820B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014004420A (en) | 2011-10-12 | 2014-07-09 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod. |
| US9161935B2 (en) | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| AU2013221304B2 (en) | 2012-02-16 | 2017-12-21 | Teva Pharmaceutical Industries Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (en) | 2012-06-05 | 2014-01-01 | Teva Pharma | Treatment of ocular inflammatory disease using laquinimod |
| TW201410244A (en) | 2012-08-13 | 2014-03-16 | Teva Pharma | Laquinimod for treatment of GABA mediated disorders |
| KR20150080509A (en) * | 2012-10-12 | 2015-07-09 | 테바 파마슈티컬 인더스트리즈 리미티드 | Laquinimod for reducing thalamic damage in multiple sclerosis |
| EA201590788A1 (en) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | AMINAL SALTS LACHINIMODA |
| KR20150119227A (en) * | 2013-02-15 | 2015-10-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | Treatment of multiple sclerosis with laquinimod |
| JP2016514162A (en) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | Laquinimod sodium crystals and improved process for their production |
| AR098924A1 (en) * | 2013-12-23 | 2016-06-22 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND TERIFLUNOMIDE |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| AU2019306828A1 (en) * | 2018-07-20 | 2021-03-11 | Merck Patent Gmbh | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US7560100B2 (en) * | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
| WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| WO2010147665A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| MX2014004420A (en) * | 2011-10-12 | 2014-07-09 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod. |
| KR20150119227A (en) * | 2013-02-15 | 2015-10-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | Treatment of multiple sclerosis with laquinimod |
-
2013
- 2013-04-29 AR ARP130101459A patent/AR090885A1/en unknown
- 2013-04-29 TW TW102115308A patent/TW201347762A/en unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/en unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/en not_active Application Discontinuation
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en active Application Filing
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/en not_active Withdrawn
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/en active Pending
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/en active Pending
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/en not_active Application Discontinuation
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/en not_active IP Right Cessation
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/en unknown
- 2013-05-01 EA EA201492010A patent/EA201492010A1/en unknown
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/en not_active Application Discontinuation
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/en unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-07-16 HK HK15106789.5A patent/HK1206246A1/en unknown
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014013039A (en) | 2015-02-04 |
| CN104284663A (en) | 2015-01-14 |
| TW201347762A (en) | 2013-12-01 |
| EP2844255A1 (en) | 2015-03-11 |
| CN105832733A (en) | 2016-08-10 |
| WO2013166166A1 (en) | 2013-11-07 |
| AU2013256352A1 (en) | 2014-11-27 |
| PE20150161A1 (en) | 2015-02-22 |
| JP2017222691A (en) | 2017-12-21 |
| AR090885A1 (en) | 2014-12-10 |
| US20160000775A1 (en) | 2016-01-07 |
| ZA201408820B (en) | 2016-06-29 |
| US20150265592A1 (en) | 2015-09-24 |
| HK1206246A1 (en) | 2016-01-08 |
| PH12014502447A1 (en) | 2015-01-12 |
| TW201804997A (en) | 2018-02-16 |
| CA2870684A1 (en) | 2013-11-07 |
| JP2015515985A (en) | 2015-06-04 |
| EP2844255A4 (en) | 2015-10-14 |
| IL235337A0 (en) | 2014-12-31 |
| US20130303569A1 (en) | 2013-11-14 |
| EA201492010A1 (en) | 2015-06-30 |
| UY34775A (en) | 2013-11-29 |
| BR112014027010A2 (en) | 2017-06-27 |
| KR20150013658A (en) | 2015-02-05 |
| CL2014002935A1 (en) | 2015-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180939T1 (en) | Combination therapy for treatment of multiple sclerosis | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis (laquinimod) | |
| HK1215375A1 (en) | Use of akkermansia for treating metabolic disorders | |
| HK1206937A1 (en) | Methods of administering pirfenidone therapy | |
| IL252547A0 (en) | Treatment of multiple sclerosis with laquinimod | |
| LT2857019T (en) | Method of treating multiple sclerosis | |
| IL234813A0 (en) | Methods for increasing efficacy of cd37-based therapy | |
| HK1218254A1 (en) | Treatment of multiple sclerosis with laquinimod | |
| PL3524260T3 (en) | Pharmaceutical compositions for treatment of inappetence | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| SI2938350T1 (en) | Medical formulation for treating hypercholesterolemia | |
| EP2897607A4 (en) | Inhibitors of beta-hydrolase for treatment of cancer | |
| IL244620A0 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| HK1210421A1 (en) | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3- | |
| HK1206633A1 (en) | Composition for treatment of warts | |
| EP2800763A4 (en) | Compositions and methods for treating multiple sclerosis | |
| SI2812351T1 (en) | Pharmaceutical composition for the treatment of multiple sclerosis | |
| IL228464A (en) | Quinolone analogs for use in the manufacture of medicaments for treating multiple sclerosis |